Monopar Appoints Susan Rodriguez Chief Commercial and Strategy Officer for H1 2026 NDA
Monopar Therapeutics has appointed Susan Rodriguez as Chief Commercial and Strategy Officer to lead its commercial strategy and infrastructure build-out. She will oversee preparations for the planned first-half 2026 FDA New Drug Application submission of ALXN1840 for Wilson disease.
1. Strategic Role Definition
In her newly created role, Susan Rodriguez will lead all commercial strategy, infrastructure and market access activities as Monopar transitions from clinical development toward commercialization.
2. NDA Submission Plans
Monopar plans to submit its New Drug Application for ALXN1840 in the first half of 2026, positioning the late-stage Wilson disease therapy for FDA review under Rodriguez’s leadership.
3. Biopharma Leadership Background
Rodriguez brings over 30 years of biopharmaceutical experience, including serving as COO of Avadel Pharmaceuticals where she contributed to its $2 billion acquisition by Alkermes, and as CCO at Ardelyx where she launched two rare disease therapies.